Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial

M. Früh*, H. B. Ris, A. Xyrafas, S. Peters, R. O. Mirimanoff, O. Gautschi, M. Pless, R. Stupp

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)1971-1972
Number of pages2
JournalAnnals of Oncology
Volume27
Issue number10
DOIs
StatePublished - Oct 2016

Funding

The trial was supported by the Swiss Government through the State Secretariat for Education, Research and Innovation, SERI. Sanofi (Switzerland) provided financial contribution and docetaxel free of charge. No funding for this Letter. MP Advisory for Sanofi, SP Honoraria from and Advisory role for: Amgen, Lilly, Pfizer, Roche, Astra Zeneca, Boehringer Ingelheim, MSD, Merk Serono, Celgene, Debiopharm, Novartis and BMS. Other authors: no conflicts. The trial was supported by the Swiss Government through the State Secretariat for Education, Research and Innovation, SERI. Sanofi (Switzerland) provided financial contribution and docetaxel free of charge.

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this